

## References

I-183

1. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2017;390:849-860.
2. Naso MF, Tomkowicz B, Perry WL, et al. Adeno-associated virus (AAV) as a vector for gene therapy. *BioDrugs*. 2017;31(4):317-334.
3. Kumaran N, Moore AT, Weleber RG, et al. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. *Br J Ophthalmol*. 2017;101(9):1147-1154.
4. Campa C, Gallenga CE, Bolletta E, et al. The role of gene therapy in the treatment of retinal diseases: a review. *Curr Gene Ther*. 2017;17(3):194-213.
5. Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. *Clin Exp Ophthalmol*. 2017;46(3):247-259.
6. Ashtari M, Nikonova ES, Marshall KA, et al. The role of the human visual cortex in assessment of the long-term durability of retinal gene therapy in follow-on RPE65 clinical trial patients. *Ophthalmology*. 2017;124(6):873- 883.
7. Le Meur G, Lebranchu P, Billaud F, et al. Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis. *Mol Ther*. 2018;26(1):256-268.
8. Maguire AM, Russell S, Wellman JA, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: Results of phase 1 and 3 trials. *Ophthalmology*. 2019;126(9):1273-1285.
9. Farmer C, Bullement A, Packman D, et al. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations: An evidence review group perspective of a NICE highly specialised technology appraisal. *Pharmacoeconomics*. 2020;38(12):1309-1318.
10. Dias M, Joo K, Kemp J, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. *Prog Retin Eye Res*. 2018;63:107-131.
11. Sodi A, Banfi S, Testa F, et al. RPE65-associated inherited retinal diseases: Consensus recommendations for eligibility to gene therapy. *Orphanet J Rare Dis*. 2021;16(1):257.
12. Luxturna® (Voretigene Neparvovec-rzyl), injection, for subretinal use [package insert]. Spark Therapeutics, Inc. Philadelphia, PA. Revised 5/2022.
13. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Voretigene Neparvovec-rzyl.
14. Micromedex DrugDex Compendium®. 2024. Voretigene Neparvovec-rzyl.